Cooperative Agreement U24FD007488
- Federal Grant Award Summary Health Research, Inc. (Roswell Park Division) received a $816,307 Project Grant award, effective September 15, 2025, through August 31, 2030, under the Family Smoking Prevention and Tobacco Control Act (TCA) Regulatory Research program (CFDA 93.077). This research project, conducted at the awardee's Buffalo, New York facility, generates scientific evidence to inform the Food and Drug Administration's regulatory authority over tobacco products by assessing the market...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $2.44 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded July 15, 2025, with completion targeted for March 31, 2030. The TEAM-UP (Tobacco Treatment Navigators Uniting with Primary Care) initiative addresses tobacco use disorder, which accounts for nearly 500,000 premature deaths annually in the United States. The...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $742,500 Project Grant (R34) to Massachusetts General Hospital on July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). This three-year pilot study, concluding June 30, 2028, will develop and test a peer recovery coaching intervention designed to promote tobacco abstinence in individuals with concurrent opioid use disorder and tobacco use disorder (MOUD-TUD). The project will adapt an...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- Federal Project Grant Award Summary Massachusetts General Hospital received a $740,451 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded May 1, 2026, with completion targeted for February 28, 2031. The award supports a randomized controlled trial evaluating the effectiveness of Community Health Worker (CHW) support delivered by existing Medicaid-funded behavioral health staff for tobacco use disorder (TUD)...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) totaling $885,824 aims to assess consumer response to smokeless tobacco modified risk marketing orders. The research activities will explore 1) consumers' exposure and reactions to authorized smokeless tobacco modified risk tobacco product (MRTP) claims, and 2) whether the MRTP claims influence smokeless tobacco demand and sensory evaluations. The project will be conducted...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded the University of Vermont & State Agricultural College a $732,462 Cooperative Agreement on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to examine a digital perinatal smoking-cessation intervention. The award funds a phased research initiative combining Phase 2 (UG3) and Phase 3 (UH3) randomized controlled trials (RCTs) to advance a smartphone-based financial-incentives...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $905,044 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded May 1, 2026, with completion targeted for April 30, 2028. This award funds a mixed-methods research study examining the current assessment and documentation of electronic nicotine delivery systems (ENDS) use in primary care settings. The study will analyze electronic...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded The Washington University a Project Grant totaling $144,372.00 under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 15, 2026, with a completion date of April 30, 2031. This K02 Career Development Award supports research and career advancement by a recently tenured investigator focused on implementing personalized tobacco use treatment approaches in real-world clinical settings. The project delivers...
- Federal Grant Award Summary Boston University Medical Campus received a $193,752 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective February 15, 2026 through January 31, 2031. The award funds research on adolescent exposure to nicotine and tobacco content on social media platforms, with the objective of developing improved exposure assessment methodologies that incorporate both youth experiences and social...
LEVERAGING CDISC INNOVATIVE APPROACHES AND EMERGING TECHNOLOGY TO EXPEDITE DEVELOPMENT OF OPEN, END-TO-END TOBACCO STANDARDS TO FACILITATE REGULATORY SUBMISSION, REVIEW AND DECISION MAKING. - PROJECT SUMMARY - CDISC TOBACCO STANDARDS PROJECT CDISC IS WELL POSITIONED TO ASSIST FDA-CTP IN ACHIEVING ALL FOUR OVERARCHING PROGRAM STRATEGIC GOALS AND PROGRAM OBJECTIVES LISTED IN RFA-FD-22-022. CDISC, FOR OVER 20 YEARS, HAS SUPPORTED OPEN, CONSENSUS BASED, STANDARDS DEVELOPMENT AND HAS MAINTAINED AND PROMOTED A WELL- DEFINED DATA STANDARDS GOVERNANCE FUNCTION REGULATED BY CDISC COP-001 STANDARDS DEVELOPMENT [7]. ALL CDISC STANDARDS DEVELOPMENT FOLLOW THIS RIGOROUS PROCESS TO ENSURE QUALITY AND FITNESS FOR USE AS WELL AS ENCOURAGE THE WIDE ADOPTION OF THE STANDARDS. LEVERAGING DEEP PREVIOUS EXPERIENCE AND THE STANDARDS DEVELOPMENT PROCESS MENTIONED ABOVE, THE CDISC STANDARDS DEVELOPMENT TEAM WILL ENGAGE STAKEHOLDERS IN THE PUBLICATION OF A TOBACCO IMPLEMENTATION GUIDE V1.0, CONFORMANCE RULES AND DEVELOPMENT AND MACHINE-READABLE BIOMEDICAL CONCEPTS (BCS) FOR CORE TOBACCO CLINICAL RESEARCH CONCEPTS. CONFORMANCE RULES, PROVIDE A CRITICAL QUALITY CHECK IN ENSURING STUDY DATA CONFORM TO CDISC STANDARDS AND BCS CAN RESULT IN A SIGNIFICANT STEP TOWARDS END-TO-END AUTOMATION AND TRACEABILITY. CDISC WILL ENSURE ALIGNMENT AND HARMONIZATION WITH THE CDISC STUDY DATA TABULATION MODEL (SDTM) FOR FDA ELECTRONIC SUBMISSIONS, CLINICAL DATA STANDARDS HARMONIZATION (CDASH), AND ADAM. THESE STANDARDS WILL BE FREELY AVAILABLE ON THE CDISC WEBSITE. THE CDISC DATA SCIENCE TEAM WILL UPDATE THE CDISC LIBRARY MODEL AND SOFTWARE TO LOAD AND GENERATE OUTPUTS FOR BCS, NEW STANDARDS CONTENT, READY-TO-IMPLEMENT METADATA, AND EXECUTABLE REPRESENTATIONS OF CONFORMANCE RULES AND REPRESENT METADATA IN ODM AND DEFINE-XML AND DEVELOP A MODEL TO INCLUDE TAUG/FOUNDATIONAL CONTENT INTO CDISC LIBRARY [35] THAT INCLUDES THE ABILITY TO GENERATE READY-TO-IMPLEMENT METADATA AND NORMATIVE STANDARDS METADATA CONTENT. CDISC WILL ALSO DEVELOP EDUCATIONAL CONTENT AND MAKE IT AVAILABLE TO IMPLEMENTERS AND UTILIZE MULTIPLE CHANNELS OF DISSEMINATION/OUTREACH TO COMMUNICATE THE RELEASE OF THE TOBACCO IMPLEMENTATION GUIDE V1.0 AND THE NEW LIBRARY FEATURES TO THE BROADER RESEARCH COMMUNITY. CDISC ALSO PROPOSES TO LEVERAGE THE FHIR-CDASH MAPPING TO ENABLE CTP TO EXPLORE APPLICATION OF REAL-WORLD DATA (EHR). CDISC'S CATALOGUE OF EXISTING STANDARDS, ALONG WITH THE INNOVATIVE APPROACHES AND TECHNOLOGY OUTLINED IN THIS APPLICATION WILL HELP TO POSITION FDA-CTP TO MOVE TOWARD OPTIMIZING ACTIVITIES THAT ADVANCE TOBACCO RESEARCH, REGULATORY SUBMISSION, REVIEW AND DECISION MAKING AND POST MARKETING SURVEILLANCE OF TOBACCO PRODUCTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/8/25 | ||
| Not listed | $0 | 11/1/23 | ||
| Not listed | $0 | 11/1/23 | ||
| Not listed | $0 | 11/1/23 | ||
| Not listed | $0 | 11/1/23 |